viral infection ↔ innate immunity at the single-cell level

<u>Marek Kochańczyk</u>, Frederic Grabowski, Zbigniew Kowek, Maciej Czerkies, Wiktor Prus, & Tomasz Lipniacki



Laboratory of Modeling in Biology and Medicine (Lipniacki lab)



Institute of Fundamental Technological Research of the...



...Polish Academy of Sciences



 \rightarrow signaling cascade culminating in activation of transcription factors IRF3 and NF-κB that jointly trigger synthesis of type I (IFNβ) and type III (IFNλ) interferons.

Secreted IFNs prompt non-infected bystander cells to prepare for infection before they encounter a virus.





Infection with RSV MOI 0.01



Motivation

	population level	single-cell level
•	IRF3 is activated by virus infection,	but IRF3 in not active in all infected cells.
•	STAT1 is activated by viral infection,	but p-STAT1 is present preferentially in cells that are not infected.
•	IFNβ produced upon viral infection,	but IFNβ does not accumulate in cells that express viral proteins (mutual exclusion).

OBJECTIVE: Investigate the **mutual exclusion** between virus proliferation and innate immune signaling within a mechanistic **computational model**. (The model needs to be stochastic and spatial.)

METHOD: We performed experiments using:

cell-population level techniques (ELISA, Western blotting, dPCR) to calibrate the rates of virus–cell (and interferon–cell) interactions

and **single-cell techniques** (multi-channel immunostaining) to capture interactions between (neighboring) cells, that give rise rise to the observed spatiotemporal organization.

Secretion of IFN_β upon RSV infection



Viral RNA triggers an innate immune signaling cascade



Viral RNA triggers an innate immune signaling cascade



IFN β/λ -induced STAT1/2 signaling attenuates viral infection



knocking out IFNλ/β receptors

IFN β/λ -induced STAT1/2 signaling attenuates viral infection



Activity of STAT1/2 attenuates the spread of RSV infection



Activity of STAT1/2 attenuates the spread of RSV infection



STAT1/2 are activated quickly; IFN β is required to sustain STAT1/2 activity



 \leftarrow **IFN**β protocols: give, give \rightarrow take, give \rightarrow take \rightarrow give

STAT1/2 are activated quickly; IFNβ is required to sustain STAT1/2 activity





Proteins of IFN-stimulated genes accumulate & degrade slowly



Proteins of IFN-stimulated genes accumulate & degrade slowly



Pre-stimulation with IFNβ impedes virus spread



Pre-stimulation with IFNβ impedes virus proliferation



Pre-stimulation with IFNβ impedes virus proliferation



 \sim +/- IFN β pre-stimulation













Transport of extracellular IFNβ

Two-storey compartments with IFN β_e above each cell





Time: 0h		
Vinf 0:	99%	(#=4058)
Vinf 1:	1%	(#=38)
VRNA 0:	100%	(#=4096)
VRNA 1:	0%	(#=0)
VRNA 2:	0%	(#=0)
VRNA 3:	0%	(#=0)
Vprot 0:	100%	(#=4096)
Vprot 1:	0%	(#=0)
Vprot 2:	0%	(#=0)
Vprot 3:	0%	(#=0)
pIRF3 0:	100%	(#=4096)
pIRF3 1:	0%	(#=0)
pIRF3 2:	0%	(#=0)
pIRF3 3:	0%	(#=0)
IFNi 0:	100%	(#=4096)
IFNi 1:	0%	(#=0)
IFNi 2:	0%	(#=0)
IFNi 3:	0%	(#=0)
pSTAT 0:	100%	(#=4096)
pSTAT 1:	0%	(#=0)
pSTAT 2:	0%	(#=0)
pSTAT 3:	0%	(#=0)
ISG 0:	100%	(#=4096)
ISG 1:	0%	(#=0)
ISG 2:	0%	(#=0)
ISG 3:	0%	(#=0)
fields:	100%	(#=4096)
dead:	0%	(#=0)
IFNeU/node	e: e:	0











Time: 10h		
Vinf 0:	99%	(#=4058)
Vinf 1:	1%	(#=38)
VRNA 0:	99%	(#=4058)
VRNA 1:	0%	(#=1)
VRNA 2:	0%	(#=4)
VRNA 3:	1%	(#=33)
Vprot 0:	100%	(#=4082)
Vprot 1:	0%	(#=8)
Vprot 2:	0%	(#=5)
Vprot 3:	0%	(#=1)
pIRF3 0:	99%	(#=4070)
pIRF3 1:	0%	(#=4)
pIRF3 2:	0%	(#=10)
pIRF3 3:	0%	(#=12)
IFNi 0:	100%	(#=4086)
IFNi 1:	0%	(#=5)
IFNi 2:	0%	(#=1)
IFNi 3:	0%	(#=4)
pSTAT 0:	95%	(#=3902)
pSTAT 1:	3%	(#=116)
pSTAT 2:	1%	(#=40)
pSTAT 3:	1%	(#=38)
ISG 0:	100%	(#=4079)
ISG 1:	0%	(#=16)
ISG 2:	0%	(#=1)
ISG 3:	0%	(#=0)
fields:	100%	(#=4096)
dead:	0%	(#=0)
IFNeU/node	e: 2:	593 22



Time: 12h			
Vinf 0:	99%	(#=4054)	
Vinf 1:	1%	(#=42)	
VRNA 0:	99%	(#=4056)	
VRNA 1:	0%	(#=2)	
VRNA 2:	0%	(#=4)	
VRNA 3:	1%	(#=34)	
Vprot 0:	99%	(#=4075)	
Vprot 1:	0%	(#=12)	
Vprot 2:	0%	(#=7)	
Vprot 3:	0%	(#=2)	
pIRF3 0:	99%	(#=4066)	
pIRF3 1:	0%	(#=4)	
pIRF3 2:	0%	(#=9)	
pIRF3 3:	0%	(#=17)	
IFNi 0:	100%	(#=4082)	
IFNi 1:	0%	(#=8)	
IFNi 2:	0%	(#=0)	
IFNi 3:	0%	(#=6)	
pSTAT 0:	89%	(#=3652)	
pSTAT 1:	7%	(#=273)	
pSTAT 2:	2%	(#=85)	
pSTAT 3:	2%	(#=86)	
ISG 0:	97%	(#=3987)	
ISG 1:	2%	(#=101)	
ISG 2:	0%	(#=5)	
ISG 3:	0%	(#=3)	
fields:	100%	(#=4096)	
dead:	0%	(#=0)	
IFNeU/node	e: e:	1559 39	



Time: 16h			
Vinf 0:	99%	(#=4045)	
Vinf 1:	1%	(#=51)	
VRNA 0:	99%	(#=4047)	
VRNA 1:	0%	(#=4)	
VRNA 2:	0%	(#=5)	
VRNA 3:	1%	(#=40)	
Vprot 0:	99%	(#=4069)	
Vprot 1:	0%	(#=11)	
Vprot 2:	0%	(#=13)	
Vprot 3:	0%	(#=3)	
pIRF3 0:	99%	(#=4065)	
pIRF3 1:	0%	(#=5)	
pIRF3 2:	0%	(#=12)	
pIRF3 3:	0%	(#=14)	
IFNi 0:	100%	(#=4076)	
IFNi 1:	0%	(#=9)	
IFNi 2:	0%	(#=5)	
IFNi 3:	0%	(#=6)	
pSTAT 0:	72%	(#=2948)	
pSTAT 1:	16%	(#=670)	
pSTAT 2:	7%	(#=271)	
pSTAT 3:	5%	(#=207)	
ISG 0:	89%	(#=3645)	
ISG 1:	9%	(#=355)	
ISG 2:	2%	(#=71)	
ISG 3:	1%	(#=25)	
fields:	100%	(#=4096)	
dead:	0%	(#=0)	
IFNeU/node	e:	4493	
IFNeL/node	2:	69	



Time: 24h		
Vinf 0:	98%	(#=3997)
Vinf 1:	2%	(#=99)
VRNA 0:	98%	(#=4015)
VRNA 1:	0%	(#=15)
VRNA 2:	0%	(#=8)
VRNA 3:	1%	(#=58)
Vprot 0:	99%	(#=4058)
Vprot 1:	0%	(#=11)
Vprot 2:	0%	(#=11)
Vprot 3:	0%	(#=16)
pIRF3 0:	99%	(#=4051)
pIRF3 1:	0%	(#=10)
pIRF3 2:	0%	(#=13)
pIRF3 3:	1%	(#=22)
IFNi 0:	100%	(#=4076)
IFNi 1:	0%	(#=2)
IFNi 2:	0%	(#=6)
IFNi 3:	0%	(#=12)
pSTAT 0:	46%	(#=1893)
pSTAT 1:	24%	(#=963)
pSTAT 2:	16%	(#=644)
pSTAT 3:	15%	(#=596)
ISG 0:	60%	(#=2456)
ISG 1:	25%	(#=1018)
ISG 2:	9%	(#=378)
ISG 3:	6%	(#=244)
fields:	100%	(#=4096)
dead:	0%	(#=0)
IFNeU/node	e: e:	10925 154



Time: 48	ßh	
Vinf 0:	94%	(#=3863)
Vinf 1:	6%	(#=233)
VRNA 0:	95%	(#=3883)
VRNA 1:	1%	(#=26)
VRNA 2:	1%	(#=34)
VRNA 3:	4%	(#=153)
Vprot 0:	98%	(#=3996)
Vprot 1:	1%	(#=35)
Vprot 2:	1%	(#=24)
Vprot 3:	1%	(#=41)
pIRF3 0:	97%	(#=3966)
pIRF3 1:	1%	(#=22)
pIRF3 2:	1%	(#=26)
pIRF3 3:	2%	(#=82)
IFNi 0:	98%	(#=4033)
IFNi 1:	0%	(#=15)
IFNi 2:	0%	(#=19)
IFNi 3:	1%	(#=29)
pSTAT 0:	11%	(#=436)
pSTAT 1:	16%	(#=643)
pSTAT 2:	27%	(#=1099)
pSTAT 3:	47%	(#=1918)
ISG 0:	4%	(#=165)
ISG 1:	11%	(#=432)
ISG 2:	21%	(#=843)
ISG 3:	65%	(#=2656)
fields:	100%	(#=4096)
dead:	0%	(#=0)
IFNeU/node	e:	



Time: 72h		
Vinf 0:	92%	(#=3787)
Vinf 1:	8%	(#=309)
VRNA 0:	93%	(#=3808)
VRNA 1:	1%	(#=27)
VRNA 2:	1%	(#=29)
VRNA 3:	6%	(#=232)
Vprot 0:	96%	(#=3938)
Vprot 1:	1%	(#=52)
Vprot 2:	1%	(#=38)
Vprot 3:	2%	(#=68)
pIRF3 0:	95%	(#=3909)
pIRF3 1:	1%	(#=40)
pIRF3 2:	1%	(#=46)
pIRF3 3:	2%	(#=101)
IFNi 0:	97%	(#=3985)
IFNi 1:	1%	(#=25)
IFNi 2:	1%	(#=29)
IFNi 3:	1%	(#=57)
pSTAT 0:	5%	(#=224)
pSTAT 1:	10%	(#=409)
pSTAT 2:	23%	(#=933)
pSTAT 3:	62%	(#=2530)
ISG 0:	0%	(#=19)
ISG 1:	2%	(#=87)
ISG 2:	11%	(#=471)
ISG 3:	86%	(#=3519)
fields:	100%	(#=4096)
dead:	0%	(#=0)
IFNeU/node	e: e:	103712 1267



Time: 96h		
Vinf 0:	90%	(#=3695)
Vinf 1:	10%	(#=401)
VRNA 0:	91%	(#=3729)
VRNA 1:	1%	(#=35)
VRNA 2:	0%	(#=17)
VRNA 3:	8%	(#=315)
Vprot 0:	94%	(#=3853)
Vprot 1:	2%	(#=80)
Vprot 2:	1%	(#=52)
Vprot 3:	3%	(#=111)
pIRF3 0:	94%	(#=3852)
pIRF3 1:	1%	(#=49)
pIRF3 2:	1%	(#=57)
pIRF3 3:	3%	(#=138)
IFNi 0:	97%	(#=3957)
IFNi 1:	1%	(#=39)
IFNi 2:	1%	(#=39)
IFNi 3:	1%	(#=61)
pSTAT 0:	5%	(#=200)
pSTAT 1:	9%	(#=354)
pSTAT 2:	22%	(#=911)
pSTAT 3:	64%	(#=2631)
ISG 0:	0%	(#=14)
ISG 1:	2%	(#=71)
ISG 2:	11%	(#=455)
ISG 3:	87%	(#=3556)
fields:	100%	(#=4096)
dead:	0%	(#=0)
IFNeU/node	e: e:	

Experiment vs. simulation – spatially

RSV MOI 0.01

RSV MOI 1.0

000

0 000000000

 \mathbf{OOO}

0

0 0



simulation

diverse

levels of pSTAT

IFNβe-producing cell

(with some vProtein

high pIRF3 and

Experiment vs. simulation: signaling versus responding cells

24 h post-infection with RSV at MOI 0.1



Experiment vs. simulation: signaling versus responding cells

24 h post-infection with RSV at MOI 0.1



Experiment vs. simulation: signaling versus responding cells



Experiment vs. simulation: antagonism of virus & immune response



24 h post-infection with RSV at indicated MOIs

Conclusion

Data from **cell-population** level experiments and **single-cell** imaging data

model of: virus ↔ innate immunity

that explains **spatial** organization and **bistable** cell responses **at the single-cell level**.

Thank you

EXPERIMENT: Zbigniew Kowek, Maciej Czerkies, Wiktor Prus MODELING: Marek Kochańczyk, Frederic Grabowski, Tomasz Lipniacki



This research is funded by the **Norwegian Financial Mechanism GRIEG-1** (grant 2019/34/H/NZ6/00699, operated by the National Science Centre, Poland).